Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,223 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,223 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $9.32, for a total transaction of $207,118.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Adrian Haigh also recently made the following trade(s):

• On Friday, April 19th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.34, for a total value of $207,553.48.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.91, for a total transaction of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.30, for a total transaction of $228,886.60.

Fennec Pharmaceuticals Stock Performance

Fennec Pharmaceuticals stock traded up $0.04 during midday trading on Monday, reaching $9.38. 164,514 shares of the company were exchanged, compared to its average volume of 111,914. The firm’s 50-day simple moving average is $10.07 and its 200-day simple moving average is $9.38. Fennec Pharmaceuticals Inc has a 1 year low of $6.30 and a 1 year high of $11.92. The company has a market capitalization of $254.20 million, a price-to-earnings ratio of -15.38 and a beta of 0.38.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). The company had revenue of $9.74 million during the quarter, compared to analysts’ expectations of $9.47 million. On average, analysts forecast that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Institutional Trading of Fennec Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of FENC. Worth Venture Partners LLC boosted its holdings in Fennec Pharmaceuticals by 52.7% in the 4th quarter. Worth Venture Partners LLC now owns 141,500 shares of the company’s stock worth $1,588,000 after acquiring an additional 48,864 shares during the period. AIGH Capital Management LLC lifted its position in shares of Fennec Pharmaceuticals by 6.9% during the third quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock worth $2,805,000 after purchasing an additional 24,069 shares in the last quarter. Eudaimonia Advisors LLC lifted its position in shares of Fennec Pharmaceuticals by 90.8% during the fourth quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock worth $367,000 after purchasing an additional 15,556 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Fennec Pharmaceuticals in the fourth quarter valued at $158,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Fennec Pharmaceuticals during the 3rd quarter valued at $50,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

FENC has been the subject of a number of research analyst reports. Craig Hallum upped their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a report on Monday, March 18th. Wedbush reaffirmed an “outperform” rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a report on Monday, March 18th. Finally, HC Wainwright boosted their target price on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, April 4th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.